ArticleOncoimmunology2013
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies.Cancers · 2026Review
- Immune Regulatory Networks and Therapy of γδ T Cells in Liver Cancer: Recent Trends and Advancements.Journal of clinical and translational hepatology · 2024Review
- An Overview of Advances in Rare Cancer Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches.Frontiers in immunology · 2023Review
- Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.Cancer cell international · 2022Review
- Article
- Clinical and Biological Implications of Cancer Stem Cells in Hepatocellular Carcinoma.Yonago acta medica · 2021Review
- Advances in the conventional clinical treatment for hepatoblastoma and therapeutic innovation.World journal of pediatric surgery · 2021Review
- Hepatoblastoma: current knowledge and promises from preclinical studies.Translational gastroenterology and hepatology · 2020Review
- Volasertib preclinical activity in high-risk hepatoblastoma.Oncotarget · 2019Article
- Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival.Journal of gastrointestinal oncology · 2018Article
- Tracking cellular and molecular changes in a species-specific manner during experimental tumor progressionOncotarget · 2018Article
- Review
- Biomimetic strategies for targeted nanoparticle delivery.Bioengineering & translational medicine · 2016Review
- Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Molecular therapy oncolytics · 2016Article
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.Oncoimmunology · 2014Review
- Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoblastoma (HB) is the most common liver cancer in children. Recurrence of HB after chemotherapy and surgery is frequent among high-risk patients and is associated with chemoresistance. Immunotherapy may improve poor treatment outcomes in HB patients. Cytotoxic leukocytes of the innate and adaptive immune system including different populations of cytotoxic T cells play a major role in fighting developing tumors. In this setting, monoclonal antibodies may be employed to specifically direct immune responses toward tumor cells. We addressed this issue by using humanized antibodies that recognize the cell surface molecule EpCAM (CD326, overexpressed in hepatic tumor cells) to enhance immune responses against HB. EpCAM was constantly expressed on HB cells and its expression was independent of previous therapy based on the DNA-damaging agent cisplatin. Co-culture assays performed with two well-described HB cell lines and tumor tissue cultures demonstrated that tumor cell lysis by γδ T cells can be dramatically augmented by applying EpCAM-specific monoclonal antibodies. These data emphasize the value of antitumor immune responses and encourage adapting immunotherapeutic regimens to improve the outcome of high risk HB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.